Takenaka T - Search Results

1

Evaluation of animal models for intestinal first-pass metabolism of drug candidates to be metabolized by CYP3A enzymes via in vivo and in vitro oxidation of midazolam and triazolam.

Kuze J, Mutoh T, Takenaka T, Oda N, Hanioka N, Narimatsu S. Kuze J, et al. Among authors: takenaka t. Xenobiotica. 2013 Jul;43(7):598-606. doi: 10.3109/00498254.2012.751517. Epub 2013 Jan 3. Xenobiotica. 2013. PMID: 23282066

2

Separate evaluation of intestinal and hepatic metabolism of three benzodiazepines in rats with cannulated portal and jugular veins: comparison with the profile in non-cannulated mice.

Kuze J, Mutoh T, Takenaka T, Morisaki K, Nakura H, Hanioka N, Narimatsu S. Kuze J, et al. Among authors: takenaka t. Xenobiotica. 2009 Nov;39(11):871-80. doi: 10.3109/00498250903215382. Xenobiotica. 2009. PMID: 19845438

3

Human small intestinal epithelial cells differentiated from adult intestinal stem cells as a novel system for predicting oral drug absorption in humans.

Takenaka T, Harada N, Kuze J, Chiba M, Iwao T, Matsunaga T. Takenaka T, et al. Drug Metab Dispos. 2014 Nov;42(11):1947-54. doi: 10.1124/dmd.114.059493. Epub 2014 Sep 8. Drug Metab Dispos. 2014. PMID: 25200868

4

Application of a Human Intestinal Epithelial Cell Monolayer to the Prediction of Oral Drug Absorption in Humans as a Superior Alternative to the Caco-2 Cell Monolayer.

Takenaka T, Harada N, Kuze J, Chiba M, Iwao T, Matsunaga T. Takenaka T, et al. J Pharm Sci. 2016 Feb;105(2):915-924. doi: 10.1016/j.xphs.2015.11.035. J Pharm Sci. 2016. PMID: 26869436

5

Development of Caco-2 cells co-expressing CYP3A4 and NADPH-cytochrome P450 reductase using a human artificial chromosome for the prediction of intestinal extraction ratio of CYP3A4 substrates.

Takenaka T, Kazuki K, Harada N, Kuze J, Chiba M, Iwao T, Matsunaga T, Abe S, Oshimura M, Kazuki Y. Takenaka T, et al. Drug Metab Pharmacokinet. 2017 Feb;32(1):61-68. doi: 10.1016/j.dmpk.2016.08.004. Epub 2016 Aug 26. Drug Metab Pharmacokinet. 2017. PMID: 28139373

6

A Drug-Drug Interaction Study to Evaluate the Effect of TAS-303 on CYP3A Activity in the Small Intestine and Liver.

Kumagai Y, Fujita T, Maeda M, Sasaki Y, Nagaoka M, Huang J, Takenaka T, Kawai M. Kumagai Y, et al. Among authors: takenaka t. J Clin Pharmacol. 2020 Jun;60(6):702-710. doi: 10.1002/jcph.1583. Epub 2020 Feb 5. J Clin Pharmacol. 2020. PMID: 32026490 Free PMC article. Clinical Trial.

7

The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.

Fujita H, Miyadera K, Kato M, Fujioka Y, Ochiiwa H, Huang J, Ito K, Aoyagi Y, Takenaka T, Suzuki T, Ito S, Hashimoto A, Suefuji T, Egami K, Kazuno H, Suda Y, Nishio K, Yonekura K. Fujita H, et al. Among authors: takenaka t. Mol Cancer Ther. 2013 Dec;12(12):2685-96. doi: 10.1158/1535-7163.MCT-13-0459. Epub 2013 Oct 18. Mol Cancer Ther. 2013. PMID: 24140932

8

[Specificity of -fetoprotein of primary hepatoma].

Fujita T, Takenaka T, Okita K, Nishioka M, Harada T. Fujita T, et al. Among authors: takenaka t. Nihon Rinsho. 1972 May;30(5):1179-85. Nihon Rinsho. 1972. PMID: 4339905 Japanese. No abstract available.

9

A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS-114.

Araki H, Takenaka T, Takahashi K, Yamashita F, Matsuoka K, Yoshisue K, Ieiri I. Araki H, et al. Among authors: takenaka t. CPT Pharmacometrics Syst Pharmacol. 2022 May;11(5):604-615. doi: 10.1002/psp4.12747. Epub 2021 Dec 23. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 34951129 Free PMC article.

10

TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models.

Yoshimura C, Muraoka H, Ochiiwa H, Tsuji S, Hashimoto A, Kazuno H, Nakagawa F, Komiya Y, Suzuki S, Takenaka T, Kumazaki M, Fujita N, Mizutani T, Ohkubo S. Yoshimura C, et al. Among authors: takenaka t. Mol Cancer Ther. 2019 Jul;18(7):1205-1216. doi: 10.1158/1535-7163.MCT-18-0644. Epub 2019 May 15. Mol Cancer Ther. 2019. PMID: 31092565

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

951 results

Search Page

Filters